| Autor: |
Conceição AL; 1. Laboratory of Genomics Studies, UNESP, São José do Rio Preto, Brazil., Babeto E; 1. Laboratory of Genomics Studies, UNESP, São José do Rio Preto, Brazil., Candido NM; 1. Laboratory of Genomics Studies, UNESP, São José do Rio Preto, Brazil., Franco FC; 1. Laboratory of Genomics Studies, UNESP, São José do Rio Preto, Brazil., de Campos Zuccari DA; 2. Center for the Study of Cancer Prognosis, FAMERP, São José do Rio Preto, Brazil., Bonilha JL; 3. Department of Pathology, FAMERP, São José do Rio Preto, Brazil., Cordeiro JA; 4. Department of Epidemiology and Collective Health, FAMERP, São José do Rio Preto, Brazil., Calmon MF; 1. Laboratory of Genomics Studies, UNESP, São José do Rio Preto, Brazil., Rahal P; 1. Laboratory of Genomics Studies, UNESP, São José do Rio Preto, Brazil. |
| Abstrakt: |
Though benign, giant cell tumor of bone (GCTB) can become aggressive and can exhibit a high mitotic rate, necrosis and rarely vascular invasion and metastasis. GCTB has unique histologic characteristics, a high rate of multinucleated cells, a variable and unpredictable growth potential and uncertain biological behavior. In this study, we sought to identify genes differentially expressed in GCTB, thus building a molecular profile of this tumor. We performed quantitative real-time polymerase chain reaction (qPCR), immunohistochemistry and analyses of methylation to identify genes that are putatively associated with GCTB. The expression of the ADAM23 and CDKN2A genes was decreased in GCTB samples compared to normal bone tissue, measured by qPCR. Additionally, a high hypermethylation frequency of the promoter regions of ADAM23 and CDKN2A in GCTB was observed. The expression of the MAP2K3, MMP14, TIMP2 and VIM genes was significantly higher in GCTB than in normal bone tissue, a fact that was confirmed by qPCR and immunohistochemistry. The set of genes identified here furthers our understanding of the molecular basis of GCTB. |
